Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Lexicon Pharmaceuticals

Evaluate

Thumbnail
June 01, 2023

US FDA approval and panel tracker: May 2023

Thumbnail
August 27, 2022

ESC 2022 – so far so similar for Farxiga and Jardiance

Astrazeneca’s SGLT2 matches Lilly and Boehringer’s rival in heart failure with preserved ejection fraction, but the big battle could be uptake.

Article image
Vantage logo
August 19, 2022

ESC 2022 preview – can Farxiga Deliver?

Astrazeneca’s SGLT2 inhibitor has hit in HFpEF, but can it outdo Jardiance?

Article image
Vantage logo
March 02, 2022

US FDA approval tracker: February 2022

Article image
Vantage logo
August 27, 2021

ESC 2021 – Jardiance blows Entresto out of the water

A 21% reduction in the risk of cardiovascular death or hospitalisation paves the way for Jardiance's approval in heart failure with preserved ejection fraction.

Article image
Vantage logo
August 20, 2021

Roxadustat shows the latest regulatory fault line split

Fibrogen’s controversial anaemia pill becomes the latest example of markedly different regulatory stances taken in Europe and the US.

Article image
Vantage logo
July 06, 2021

Jardiance prevails where Entresto could not

Article image
Vantage logo
May 17, 2021

ACC 2021 – Esbriet could Pirouette into heart failure

The IPF drug shows surprising promise in heart failure with preserved ejection fraction.

Article image
Vantage logo
January 15, 2021

The biotech resurrection continues

Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.

Article image
Vantage logo
November 17, 2020

AHA 2020 – sotagliflozin wins come too late for Lexicon

But the Soloist trial suggests a benefit in heart failure with preserved ejection fraction, which might be good news for Lexicon’s SGLT2 rivals.

Article image
Vantage logo
March 30, 2020

Farxiga could tie a fourth string to its bow

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up